Cargando…
X66, a novel N-terminal heat shock protein 90 inhibitor, exerts antitumor effects without induction of heat shock response
Heat shock protein 90 (HSP90) is essential for cancer cells to assist the function of various oncoproteins, and it has been recognized as a promising target in cancer therapy. Although the HSP90 inhibitors in clinical trials have shown encouraging clinical efficacy, these agents induce heat shock re...
Autores principales: | Zhao, Zhixin, Zhu, Jianming, Quan, Haitian, Wang, Guimin, Li, Bo, Zhu, Weiliang, Xie, Chengying, Lou, Liguang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045423/ https://www.ncbi.nlm.nih.gov/pubmed/27105490 http://dx.doi.org/10.18632/oncotarget.8818 |
Ejemplares similares
-
Design, Synthesis and Pharmacological Evaluation of Novel Hsp90N‐terminal Inhibitors Without Induction of Heat Shock Response
por: Liu, Peng, et al.
Publicado: (2019) -
Y‐632 inhibits heat shock protein 90 (Hsp90) function by disrupting the interaction between Hsp90 and Hsp70/Hsp90 organizing protein, and exerts antitumor activity in vitro and in vivo
por: Wang, Wenqian, et al.
Publicado: (2016) -
Heat shock protein 90 in neurodegenerative diseases
por: Luo, Wenjie, et al.
Publicado: (2010) -
Heat Shock Protein 90 in Alzheimer's Disease
por: Ou, Jiang-Rong, et al.
Publicado: (2014) -
Heat shock protein 90 inhibition in the endothelium
por: Barabutis, Nektarios
Publicado: (2023)